AlphaMaven

Company Logo'

Cannabis

GreenTech Labs - Pre IPO Investment In The Medical Cannabis Sector

Request More Information

Investment Overview

Strategy Description

GreenTech Labs is at the forefront of the Cannabis Based Medicine ('CBM') revolution. We are a highly focused biotech company with a pharmaceutical grade drug delivery (globally patented, fast onset, GRAS approved, nano-tech sublingual wafer) system, our own international Randomised Control Trial and Medical Education Platform (located in Cape Town, London and Denmark), with immediate and medium pipeline of 3 OTC and RX medications and one wellness / adult use (USA and Canada) ready for commercialisation and / the execution of our already designed Phase II / III trial program. We have our own EU - GMP lab & commercial production facility supported by one of the EMEA's largest pharmaceutical companies to advance and produce our products combined with our founding partner having Africa's largest and most advanced hospital network we capitalise on through our Trial Platform (cost and time savings for trials and drug development), located in Cape Town. Our products are all at Proof of Concept (S6) stage and target the following: 1. Breakthrough Cancer Pain (BTcP) & CINV (Rx) - CBM formulation delivered through our WaferMat (funds deployed for Phase I-IIA combined). 2. Sleep Disorders - Somnipathy (OTC) - Non THC CBM formulation delivered through our WaferMat (post funding commercialisation ready). 3. Scaffolding Design - Chronic Wound Care (OTC / Medical Device) - World's first CBM for Chronic Wounds (Pre-Clinical on the cannabinoid formulation, delivery scaffolding POC and market ready) 4. CannaMatt for the N. American Wellness & Adult Use Market - where delivery technology meets the benefits of cannabis Our international trial and drug development team have 30 years plus experience in cannabinoid, pharmaceutical and drug delivery sciences with our pain team having experience at GW Pharma, British and Danish Pain Societies and our Principal Investigator and CMO is the world's first clinical pharmacologist to also be awarded a Masters in Cannabinoid Science from the American College of Clinical Pharmacologists. GreenTech - We aim at disrupting both the Medical Cannabis and Pharmaceutical Sectors by merging state of the art delivery science with the benefits of the latest medical cannabis formulation and research.
Principals

Investment Highlights

Investment Category

Private Equity, Cannabis

Investment Strategy

Disruptive Technologies

Investment Structure

Direct Deal, SPV

Objective

Our Performance Goal
Target Return 3-5X

Investment Opportunity

What We Believe
Due to our pharmaceutical medical cannabis drug pipeline and assets, we aim on IPO'ing in 12 months at a projected market value of $300 - 500 million.

Return Driver - Alpha

Our Edge
Experience, Technical Knowledge, Management Capability
Implementation of Strategy
Tactical Approach

Market Sector Exposure

Private Equity, Healthcare

Geographical Exposure

Global

Average Timeframe

18-24 Months

Risk Management

Active management
Investment Structure

Legal Structure

LLC

Domicile

United Kingdom
Service Providers

Administrator

Jersey Trust Company

Auditor

JTC - London

Legal

Charles Russell Speechly's of London

Custodian/Bank

Barclays
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.
Not a member yet?

Join AlphaMaven

The Premier Alternative Investment
Research and Due Diligence Platform for Investors

Free Membership for Qualified Investors and Industry Participants
  • Easily Customize Content to Match Your Investment Preferences
  • Breaking News 24/7/365
  • Daily Newsletter & Indices
  • Alternative Investment Listings & LeaderBoards
  • Industry Research, Due Diligence, Videos, Webinars, Events, Press Releases, Market Commentary, Newsletters, Fact Sheets, Presentations, Investment Mandates, Video PitchBooks & More!
  • Company Directory
  • Contact Directory
  • Member Posts & Publications
  • Alpha University Video Series to Expand Investor Knowledge
  • AUM Accelerator Program (designed for investment managers)
  • Over 450K+ Industry Headlines, Posts and Updates
Sign Up Now
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.